Patents by Inventor Ravi Mysore Shanker

Ravi Mysore Shanker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for annealing amorphous atorvastatin
    Patent number: 9932307
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 3, 2018
    Assignee: Pfizer Inc.
    Inventors: Renuka Devi Reddy, Evgenyi Shalaev, Ravi Mysore Shanker, Carl Bernard Ziegler
  • Process For Annealing Amorphous Atorvastatin
    Publication number: 20160332965
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Application
    Filed: July 27, 2016
    Publication date: November 17, 2016
    Inventors: Renuka Devi Reddy, Evgenyi Shalaev, Ravi Mysore Shanker, Carl Bernard Ziegler
  • Process for annealing amorphous atorvastatin
    Patent number: 9428455
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: August 30, 2016
    Assignee: Pfizer Inc.
    Inventors: Renuka Devi Reddy, Evgenyi Shalaev, Ravi Mysore Shanker, Carl Bernard Ziegler
  • Process For Annealing Amorphous Atorvastatin
    Publication number: 20150274659
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Application
    Filed: April 16, 2015
    Publication date: October 1, 2015
    Inventors: Renuka Devi Reddy, Evgenyi Shalaev, Ravi Mysore Shanker, Carl Bernard Ziegler
  • Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase
    Patent number: 8828438
    Abstract: A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: September 9, 2014
    Assignee: Bend Research, Inc.
    Inventors: Dwayne Thomas Friesen, Bruno Caspar Hancock, Rodney James Ketner, David Keith Lyon, James Alan Shriver Nightingale, Ravi Mysore Shanker
  • SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE
    Publication number: 20100003331
    Abstract: A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: September 3, 2009
    Publication date: January 7, 2010
    Applicant: Pfizer Inc.
    Inventors: Imran Ahmed, Leah Elizabeth Appel, Walter Christian Babcock, Dwayne Thomas Friesen, Scott Herbig, David Keith Lyon, Sheri L. Shamblin, Ravi Mysore Shanker, Daniel Tod Smithey, Steven C. Sutton, Avinash Govind Thombre, Kenneth C. Waterman, Jaymin C. Shah, Parag Suresh Shah, Peter Wisniecki, Dawn Renee Wagner
  • Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase
    Publication number: 20090118328
    Abstract: A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-conenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment.
    Type: Application
    Filed: May 22, 2006
    Publication date: May 7, 2009
    Applicant: BEND RESEARCH, INC.
    Inventors: Dwayne Thomas Friesen, Bruno Caspar Hancock, Rodney James Ketner, David Keith Lyon, James Alan Shriver Nightingale, Ravi Mysore Shanker
  • N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
    Patent number: 7521456
    Abstract: The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: April 21, 2009
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Douglas John Meldrum Allen, Timothy Norris, Jeffrey William Raggon, Dinos Paul Santafianos, Ravi Mysore Shanker
  • Solubilized sertraline compositions
    Publication number: 20040208926
    Abstract: Compositions of matter comprising sertraline and a solubilizing agent which increases the solubility of sertraline in aqueous chloride ion-containing use environments.
    Type: Application
    Filed: May 4, 2004
    Publication date: October 21, 2004
    Applicant: Pfizer Inc
    Inventors: Dwayne Thomas Friesen, Scott Max Herbig, Ravi Mysore Shanker, James Blair West
  • N- (3-ethynylphenyl) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine mesylate anhydrate and monohydrate
    Publication number: 20040102463
    Abstract: The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.
    Type: Application
    Filed: November 17, 2003
    Publication date: May 27, 2004
    Applicant: OSI Pharmaceuticals, Inc.
    Inventors: Douglas John Meldrum Allen, Timothy Norris, Jeffrey William Raggon, Dinos Paul Santafianos, Ravi Mysore Shanker
  • N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
    Patent number: 6706721
    Abstract: The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: March 16, 2004
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Douglas John Meldrum Allen, Timothy Norris, Jeffrey William Raggon, Dinos Paul Santafianos, Ravi Mysore Shanker
  • Encapsulated solution dosage forms of sertraline
    Publication number: 20030133974
    Abstract: Dosage forms of sertraline encapsulated in a water-immiscible vehicle shorten Tmax and/or reduce side effects and/or decrease sertraline precipitation in chloride ion-containing use environments such as the gastrointestinal tract.
    Type: Application
    Filed: December 5, 2002
    Publication date: July 17, 2003
    Inventors: William John Curatolo, Ravi Mysore Shanker